A PHASE IIa clinical trial of eight patients at Singapore General Hospital has showed that pSivida’s BrachySil product is safe and effectively reduces tumours.
The first four patients, all with inoperable liver cancer, showed no product related adverse side effects and up to 60 per cent regression of their tumours.
Those patients were reviewed three months after administration.
A key finding of the study was that the radioactive biosilicon particles remained in the tumour with no or, at worst, insignificant radioactive leakage.
BrachySil is expected to be on the market worldwide during 2007, initially for liver cancer and later for the treatment of a wider variety of cancers involving solid tumours.